Scientific News Boston Scientific Lifts Sales Outlook, Notes Key Approval Of Afib Device With Minnesota Ties
Search Related Content
Sorry, Your Requested Page Was Not Found. Greetings! We apologize for the inconvenience, but the page, Scientific News Boston Scientific Lifts Sales Outlook, Notes Key Approval Of Afib Device With Minnesota Ties is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3-18 months after their creation date. We prefer to keep content fresh and current, rather than holding onto outdated news. Thanks for visiting today.Search RobinsPost News & Noticias
Boston Scientific lifts FY25 outlook amid continued cardiovascular boom
Boston achieved a 22.4% growth in its cardiovascular business in Q3, continuing the segment’s growth trend in 2025 due to the ongoing adoption of its Farapulse PFA system. Read More
Boston Scientific lifts 2025 outlook following 29% Q2 cardiovascular profit rise
Boston Scientific has raised its 2025 profit outlook to between $2.95 and $2.99 per share amid strong Q2 performance in its cardiovascular unit, driven in large part by the uptake of its Farapulse ... Read More
Boston Scientific Lifts Annual Profit Forecast, Sees Smaller Tariff Impact
(Reuters) -Boston Scientific raised its annual profit forecast on Wednesday, banking on strong demand for its heart devices, and trimmed its expectation for tariff-related costs to half of the ... Read More
Boston Scientific lifts annual profit forecast on strong demand for heart devices
Boston Scientific raised its annual profit forecast on Wednesday, after beating third-quarter profit estimates on strong demand for its heart devices, sending its shares up 4.1%. Read More
Boston Scientific rises as cardiology sales drive Q3 beat, guidance boost
Boston Scientific (BSX) stock rises as the company beats Q3 forecasts and raises full-year outlook thanks to strong cardiology sales. Read more here. Read More
Boston Scientific Reports Higher Profit Margins In Q2, Lifts Guidance
Stronger‑than‑expected sales and raised full‑year guidance underscore Boston Scientific Corporation‘s (NYSE:BSX) momentum—and hint at where its next product wins may come. Boston Scientific on ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus